Drug Profile
Research programme: wound healing agents - Helix BioMedix
Alternative Names: HB-107Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Helix BioMedix
- Class Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported Burns; Wounds
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Burns in USA (Topical, Gel)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Wounds in USA (Topical, Gel)
- 10 Oct 2005 This programme is still in active development